Insilico Medicine Inc. has disclosed substituted thiazole compounds acting as cyclin-dependent kinase (CDK) inhibitors potentially useful for the treatment of cancer. Insilico Medicine identifies CDK2 ...

13, 2025 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, a next-generation cell cycle control company developing INX-315, a novel, potent and selective CDK2 inhibitor for the treatment of advanced and ...

RESEARCH TRIANGLE PARK, N.C., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, a next-generation cell cycle control company developing INX-315, a novel, potent and selective CDK2 inhibitor for the ...

The dual mechanism of action results in deep and ... leading to increased potency and selectivity compared to other CDK2 inhibitors. ETX-197/BG-68501 shows tight binding (slow off-rate) for ...